论文部分内容阅读
在一项旨在考察阿利克仑能否降低心血管系统疾病和肾病死亡率的、名为ALTITUDE的临床研究中,2型糖尿病合并肾病的患者被随机分为阿利克仑(300 mg.d-1)治疗组(n=4 283)和安慰剂组(n=4 296),所有患者同时还接受血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)。
In a clinical trial called ALTITUDE designed to investigate whether aliskiren can reduce cardiovascular system disease and nephropathy mortality, patients with type 2 diabetes mellitus and nephropathy were randomized to aliskiren (300 mg.d- 1) treated patients (n = 4 283) and placebo (n = 4 296). All patients also received either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB).